CRESCENT BIOPHARMA, INC. — Director's Dealing 2021

Jan 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2021-01-20

Reporting Person: Magnani John L. (SVP of Research, CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-20	Common Stock	A	34500	$0.00	Acquired	324260	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-20	Employee Stock Option (right to buy)	$3.81	A	69000	Acquired	2031-01-19	Common Stock (69000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4845	Indirect

Footnotes

F1: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

F2: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date.

F3: These shares are held by GlycoTech Corporation, of which the reporting person is the sole stockholder.

F4: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.